Recombinant Human Siglec-5 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Siglec-5 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. Kelm, S. et al. (1994) Current Biology 4:965. The ED₅₀ for this effect is 1‑4 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived human Siglec-5/CD170 protein
  

  Human Siglec-5 (Glu17-Thr434) Accession # O15389	IEGRID	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O15389
• N-terminal Sequence: Glu17
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: SIGLEC5
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 73 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 100-110 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Siglec-5 Fc Chimera Protein, CF

• CD170 antigen
• CD170
• CD33 antigen-like 2
• CD33L2
• CD33L2OB binding protein-2
• OBBP2
• OB-BP2OB-binding protein 2
• OBBP2sialic acid-binding Ig-like lectin 5
• Obesity-binding protein 2
• sialic acid binding Ig-like lectin 5
• sialic acid-binding immunoglobulin-like lectin 5
• Siglec5
• Siglec-5

Background

Siglecs (1) (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins (2) belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding (3), followed by varying numbers of Ig-like C2-type domains (1, 4). Eleven human Siglecs have been cloned and characterized (1, 4). They are sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a) and the Siglec-5 to 11 (4, 5, 7). To date, no Siglec has been shown to recognized any cell surface ligand other than sialic acids, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Siglec-5 to 11 share a high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. They are collectively referred to as CD33-related Siglecs. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system (4, 5). This fact, together with the presence of two conserved immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasma tails, suggests that CD33-related Siglecs are involved in the regulation of cellular activation within the immune system.

Human Siglec-5 cDNA encodes a 551 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, three Ig-like C2-type domains, a transmembrane region and a cytoplasma tail (6). Siglec-5 exists as a disulfide-linked homodimer on the cell surface and is expressed on monocytes, neutrophils and B cells (4, 5, 6). It binds equally well to both alpha 2,3- and alpha 2,6-linked sialic acid (6).

1. Crocker, P.R. et al. (1998) Glycobiology 8:v.
2. Powell, L.D. et al. (1995) J. Biol. Chem. 270:14243.
3. May, A.R. et al. (1998) Mol. Cell 1998. 1:719.
4. Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
5. Crocker, P.R. et al. (2001) Immunology 103:137.
6. Cornish, A.L. et al. (1998) Blood 92:2123.
7. Angata, T. et al. (2002) J. Biol Chem. 277:24466.

Publications for Siglec-5/CD170 (1072-SL)(10)

Publications using 1072-SL

• Benucci, B;Spinello, Z;Calvaresi, V;Viviani, V;Perrotta, A;Faleri, A;Utrio Lanfaloni, S;Pansegrau, W;d'Alterio, L;Bartolini, E;Pinzuti, I;Sampieri, K;Giordano, A;Rappuoli, R;Pizza, M;Masignani, V;Norais, N;Maione, D;Merola, M; Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion mBio 2024-07-23 [PMID: 39041817] (Bioassay, Bacteria)
• Lozano-Rodríguez, R;Avendaño-Ortíz, J;Montalbán-Hernández, K;Ruiz-Rodríguez, JC;Ferrer, R;Martín-Quirós, A;Maroun-Eid, C;González-López, JJ;Fàbrega, A;Terrón-Arcos, V;Gutiérrez-Fernández, M;Alonso-López, E;Cubillos-Zapata, C;Fernández-Velasco, M;Pérez de Diego, R;Pelegrin, P;García-Palenciano, C;Cueto, FJ;Del Fresno, C;López-Collazo, E; The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis EBioMedicine 2023-10-25 [PMID: 37890368] (Bioassay, Human)
• Chan, C;Lustig, M;Jansen, JHM;Garcia Villagrasa, L;Raymakers, L;Daamen, LA;Valerius, T;van Tetering, G;Leusen, JHW; Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9 Cancers 2023-06-29 [PMID: 37444515] (Bioassay, Human)
• E Michaud, L Waeckel, R Gayet, R Goguyer-De, B Chanut, F Jospin, K Bathany, M Monnoye, C Genet, A Prier, C Tokarski, P Gérard, X Roblin, N Rochereau, S Paul Alteration of microbiota antibody-mediated immune selection contributes to dysbiosis in inflammatory bowel diseases Embo Molecular Medicine, 2022-07-04;0(0):e15386. 2022-07-04 [PMID: 35785473] (Bioassay, Human)
• J Terävä, L Tiainen, U Lamminmäki, PL Kellokumpu, K Pettersson, K Gidwani Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma PLoS ONE, 2019-07-25;14(7):e0219480. 2019-07-25 [PMID: 31344060] (Bioassay, Human)
• Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity Sci Rep, 2016-11-28;6(0):37953. 2016-11-28 [PMID: 27892504] (Bioassay, Human)
• Chen , Guo-Yun, Brown , Nicholas, Wu , Wei, Khedri , Zahra, Yu , Hai, Chen , Xi, van de Vlekkert , Diantha, D'Azzo , Alessand, Zheng , Pan, Liu , Yang Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife, 2014-09-03;3(0):e04066. 2014-09-03 [PMID: 25187624] (Bioassay, Human)
• Zou Z, Chastain A, Moir S Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids. PLoS ONE, 2011-09-08;6(9):e24559. 2011-09-08 [PMID: 21931755] (Surface Plasmon Resonance, Virus)
• Nordstrom T, Movert E, Olin AI, Ali SR, Nizet V, Varki A, Areschoug T Human Siglec-5 inhibitory receptor and immunoglobulin A (IgA) have separate binding sites in streptococcal beta protein. J. Biol. Chem., 2011-07-27;286(39):33981-91. 2011-07-27 [PMID: 21795693] (Surface Plasmon Resonance, Western Blot (Detection), Bacteria)
• Zhuravleva MA, Trandem K, Sun PD Structural implications of Siglec-5-mediated sialoglycan recognition. J. Mol. Biol., 2007-10-11;375(2):437-47. 2007-10-11 [PMID: 18022638] (Surface Plasmon Resonance, Human)

Bioinformatics

• Gene Symbol: SIGLEC5
• Uniprot:
  • O15389(Human)